<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36768956</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Rituximab, Intravitreal Bevacizumab and Laser Photocoagulation for Treatment of Macrophage Activation Syndrome and Retinal Vasculitis in Lupus: A Case Report.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2594</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24032594</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) most commonly manifests as mild to moderate disease with severe manifestations such as diffuse alveolar hemorrhage, central nervous system vasculitis, macrophage activation syndrome (MAS) or retinal vasculitis (RV) with visual disturbances occurring in a significantly smaller proportion of patients, most of whom have a poor outcome. Macrophage activation syndrome and RV are insufficiently early and rarely recognized presentations of lupus-consequently there are still no treatment recommendations. Here we present the course of diagnosis and treatment of a patient with an SLE flare that resulted in both life-threatening disease (MAS) and vision-threatening disease (RV). The patient was successfully treated with systemic immunosuppressives, a high dose of glucocorticoids and rituximab (RTX), in parallel with intraocular therapy, intravitreal bevacizumab (BEV) and laser photocoagulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iki&#x107; Matija&#x161;evi&#x107;</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine Clinic, University Hospital Sveti Duh, 10 000 Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kili&#x107;</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Internal Medicine Clinic, University Hospital Sveti Duh, 10 000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iki&#x107;</LastName><ForeName>Lucija</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Physiology, University of Applied Health Sciences, 10 000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gali&#x107;</LastName><ForeName>Iva</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University Eye Clinic, University Hospital Sveti Duh, 10 000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brzovi&#x107; &#x160;ari&#x107;</LastName><ForeName>Vlatka</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University Eye Clinic, University Hospital Sveti Duh, 10 000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gali&#x107;</LastName><ForeName>Edvard</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5707-0961</Identifier><AffiliationInfo><Affiliation>Internal Medicine Clinic, University Hospital Sveti Duh, 10 000 Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber><NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D031300" MajorTopicYN="Y">Retinal Vasculitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055501" MajorTopicYN="Y">Macrophage Activation Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008028" MajorTopicYN="N">Light Coagulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007834" MajorTopicYN="N">Lasers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-VEGF</Keyword><Keyword MajorTopicYN="N">bevacizumab</Keyword><Keyword MajorTopicYN="N">hemophagocytic lymphohistiocytosis</Keyword><Keyword MajorTopicYN="N">laser photocoagulation</Keyword><Keyword MajorTopicYN="N">macrophage activation syndrome</Keyword><Keyword MajorTopicYN="N">retinal vasculitis</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36768956</ArticleId><ArticleId IdType="pmc">PMC9916420</ArticleId><ArticleId IdType="doi">10.3390/ijms24032594</ArticleId><ArticleId IdType="pii">ijms24032594</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Turk M.A., Hayworth J.L., Nevskaya T., Pope J.E. Ocular manifestations in rheumatoid arthritis, connective tissue disease, and vasculitis: A systematic review and metaanalysis. J. Rheumatol. 2021;48:25&#x2013;34. doi: 10.3899/jrheum.190768.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.190768</ArticleId><ArticleId IdType="pubmed">32358156</ArticleId></ArticleIdList></Reference><Reference><Citation>Dammacco R. Systemic lupus erythematosus and ocular involvement: An overview. Clin. Exp. Med. 2018;18:135&#x2013;149. doi: 10.1007/s10238-017-0479-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-017-0479-9</ArticleId><ArticleId IdType="pubmed">29243035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashiri H., Karimi N., Mostafaei S., Baghdadi A., Nejadhosseinian M., Faezi S.T. Retinopathy in newly-diagnosed systemic lupus erythematosus: Should we screen for ocular involvement? BMC Rheumatol. 2021;5:34. doi: 10.1186/s41927-021-00203-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-021-00203-5</ArticleId><ArticleId IdType="pmc">PMC8485475</ArticleId><ArticleId IdType="pubmed">34593048</ArticleId></ArticleIdList></Reference><Reference><Citation>Palejwala N.V., Walia H.S., Yeh S. Ocular manifestations of systemic lupus erythematosus: A review of the literature. Autoimmune Dis. 2012;2012:290898. doi: 10.1155/2012/290898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/290898</ArticleId><ArticleId IdType="pmc">PMC3395333</ArticleId><ArticleId IdType="pubmed">22811887</ArticleId></ArticleIdList></Reference><Reference><Citation>Au A., O&#x2019;Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: Associations, visual outcomes, complications and treatment. Clin. Exp. Ophthalmol. 2004;32:87&#x2013;100. doi: 10.1046/j.1442-9071.2004.00766.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1442-9071.2004.00766.x</ArticleId><ArticleId IdType="pubmed">14746601</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilaiyuk S., Sirachainan N., Wanitkun S., Pirojsakul K., Vaewpanich J. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: A case-based review. Clin. Rheumatol. 2013;32:899&#x2013;904. doi: 10.1007/s10067-013-2227-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-013-2227-1</ArticleId><ArticleId IdType="pubmed">23483294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn S.S., Yoo B.W., Jung S.M., Lee S.W., Park Y.B., Song J.J. In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome. Semin. Arthritis Rheum. 2017;47:216&#x2013;221. doi: 10.1016/j.semarthrit.2017.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2017.02.002</ArticleId><ArticleId IdType="pubmed">28268026</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz A., Castaneda E.E., Ahmad N., Veerapalli H., Rockferry A.G., Lankala C.R., Hamid P. Exploring macrophage activation syndrome secondary to systemic lupus erythematosus in adults: A systematic review of the literature. Cureus. 2021;13:e18822. doi: 10.7759/cureus.18822.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.18822</ArticleId><ArticleId IdType="pmc">PMC8592789</ArticleId><ArticleId IdType="pubmed">34804679</ArticleId></ArticleIdList></Reference><Reference><Citation>Henter J.I., Horne A., Aric&#xf3; M., Egler M., Filipovich A.H., Imashuku S., Ladisch S., McClain K., Webb D., Winiarski J., et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer. 2007;48:124&#x2013;131. doi: 10.1002/pbc.21039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.21039</ArticleId><ArticleId IdType="pubmed">16937360</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardet L., Galicier L., Lambotte O., Marzac C., Aumont C., Chahwan D., Coppo P., Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613&#x2013;2620. doi: 10.1002/art.38690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38690</ArticleId><ArticleId IdType="pubmed">24782338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravelli A., Minoia F., Dav&#xec; S., Horne A., Bovis F., Pistorio A., Aric&#xf2; M., Avcin T., Behrens E.M., De Benedetti F., et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68:566&#x2013;576. doi: 10.1002/art.39332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39332</ArticleId><ArticleId IdType="pubmed">26314788</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodi A., Dav&#xec; S., Pringe A.B., Pistorio A., Ruperto N., Magni-Manzoni S., Miettunen P., Bader-Meunier B., Espada G., Sterba G., et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60:3388&#x2013;3399. doi: 10.1002/art.24883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24883</ArticleId><ArticleId IdType="pubmed">19877067</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter S.J., Tattersall R.S., Ramanan A.V. Macrophage activation syndrome in adults: Recent advances in pathophysiology, diagnosis and treatment. Rheumatology. 2019;58:5&#x2013;17. doi: 10.1093/rheumatology/key006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key006</ArticleId><ArticleId IdType="pubmed">29481673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wafa A., Hicham H., Naoufal R., Hajar K., Rachid R., Souad B., Mouna M., Zoubida M.T., Mohamed A. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 20 Moroccan adult patients. Clin. Rheumatol. 2022;41:2021&#x2013;2033. doi: 10.1007/s10067-022-06055-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06055-9</ArticleId><ArticleId IdType="pubmed">35179662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavand P.E., Serio I., Arnaud L., Costedoat-Chalumeau N., Carvelli J., Dossier A., Hinschberger O., Mouthon L., Le Guern V., Korganow A.S., et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmun. Rev. 2017;16:743&#x2013;749. doi: 10.1016/j.autrev.2017.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.05.010</ArticleId><ArticleId IdType="pubmed">28483541</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu A.-C., Yang Y., Li M.-T., Jia Y., Chen S., Ye S., Zeng X.-Z., Wang Z., Zhao J.-X., Liu X.-Y., et al. Macrophage activation syndrome in systemic lupus erythematosus: A multicenter, case-control study in China. Clin. Rheumatol. 2018;37:93&#x2013;100. doi: 10.1007/s10067-017-3625-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-017-3625-6</ArticleId><ArticleId IdType="pubmed">28409239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerkvaleekul B., Vilaiyuk S. Macrophage activation syndrome: Early diagnosis is key. Open Access Rheumatol. 2018;10:117&#x2013;128. doi: 10.2147/OARRR.S151013.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S151013</ArticleId><ArticleId IdType="pmc">PMC6124446</ArticleId><ArticleId IdType="pubmed">30214327</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Wen Y., Arevalo Molina A.B., Dahal P., Leuprecht L., Bsrat M. Macrophage activation syndrome, glomerulonephritis, pericarditis, and retinal vasculitis as initial presentation of systemic lupus erythematosus. Case Rep. Med. 2018;2018:5979386. doi: 10.1155/2018/5979386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/5979386</ArticleId><ArticleId IdType="pmc">PMC6178166</ArticleId><ArticleId IdType="pubmed">30356389</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah K., Porter A., Takhar G., Reddy V. Case of using mycophenolate in combination with steroids for concurrent macrophage activation syndrome and lupus flare. BMJ Case Rep. 2020;13:e231554. doi: 10.1136/bcr-2019-231554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2019-231554</ArticleId><ArticleId IdType="pmc">PMC7167458</ArticleId><ArticleId IdType="pubmed">32269047</ArticleId></ArticleIdList></Reference><Reference><Citation>Deaner J.D., Zeft A.S., Emami-Naeini P., Lowder C.Y. Visual recovery and vascular reperfusion after vaso-occlusive retinopathy from anti-phospholipid syndrome associated with systemic lupus erythematosus. Am. J. Ophthalmol. Case Rep. 2020;19:100763. doi: 10.1016/j.ajoc.2020.100763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajoc.2020.100763</ArticleId><ArticleId IdType="pmc">PMC7287235</ArticleId><ArticleId IdType="pubmed">32551401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermakova N.A., Alekberova Z.S., Kosheleva N.M., Reshetniak T.N. Osobennosti porazheniia sosudov setchatki pri sistemno&#x12d; krasno&#x12d; volchanke [Characteristics of retinal vascular involvement in systemic lupus erythematosus] Vestn. Oftalmol. 2001;117:21&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11510158</ArticleId></ArticleIdList></Reference><Reference><Citation>Talat L., Lightman S., Tomkins-Netzer O. Ischemic retinal vasculitis and its management. J. Ophthalmol. 2014;2014:197675. doi: 10.1155/2014/197675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/197675</ArticleId><ArticleId IdType="pmc">PMC4009272</ArticleId><ArticleId IdType="pubmed">24839552</ArticleId></ArticleIdList></Reference><Reference><Citation>Junga Z., Stitt R., Tracy C., Keith M. Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus. BMJ Case Rep. 2017;2017:bcr2017221347. doi: 10.1136/bcr-2017-221347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2017-221347</ArticleId><ArticleId IdType="pmc">PMC5624074</ArticleId><ArticleId IdType="pubmed">28827301</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakshi J., Hassan S., D&#x2019;Cruz D., Chan A. Rituximab therapy in refractory macrophage activation syndrome secondary to systemic lupus erythematosus. Lupus. 2013;22:1544&#x2013;1546. doi: 10.1177/0961203313504634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313504634</ArticleId><ArticleId IdType="pubmed">24014570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman R.A., Denniston A.K., Yee C.S., Toescu V., Murray P.I., Gordon C. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy. Lupus. 2010;19:327&#x2013;329. doi: 10.1177/0961203309347332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309347332</ArticleId><ArticleId IdType="pubmed">19900982</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K., Lam W.C., Urowitz M.B., Gladman D.D. Rituximab for sight-threatening lupus-related retinal vasculitis. J. Clin. Rheumatol. 2018;24:93&#x2013;94. doi: 10.1097/RHU.0000000000000600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000600</ArticleId><ArticleId IdType="pubmed">29059086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali Dhirani N., Ahluwalia V., Somani S. Case of combination therapy to treat lupus retinal vasculitis refractory to steroids. Can. J. Ophthalmol. 2017;52:e13&#x2013;e15. doi: 10.1016/j.jcjo.2016.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcjo.2016.07.027</ArticleId><ArticleId IdType="pubmed">28237161</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth G., Chengappa K.G., Misra D.P., Babu R., Belani P., Shanoj K.C., Kumar G., Negi V.S. Lupus retinopathy: A marker of active systemic lupus erythematosus. Rheumatol. Int. 2018;38:1495&#x2013;1501. doi: 10.1007/s00296-018-4083-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-018-4083-4</ArticleId><ArticleId IdType="pubmed">29948002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>